Target intelligence / Profile preview

Arylacetamide deacetylase pseudogene 1

Molecular classification: Other (pseudogene)

Overview

Arylacetamide deacetylase pseudogene 1 (AADACP1) is a non-coding genetic element derived from the arylacetamide deacetylase gene (AADAC)[5]. Unlike its protein-coding parent gene, which encodes an enzyme involved in drug and lipid metabolism, the pseudogene does not produce a functional protein and is not involved in therapeutic targeting. Pseudogenes like AADACP1 arise from duplication or retrotransposition events and typically retain sequence similarity to their parent genes but are transcriptionally inactive, lacking the ability to catalyze biochemical reactions or participate in signaling pathways.

Other names: AADACP1

Beyond the preview

Go deeper on Arylacetamide deacetylase pseudogene 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arylacetamide deacetylase pseudogene 1.

Explore the full profile